173 related articles for article (PubMed ID: 38701318)
1. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
Ding W; Chen L; Xia J; Pei B; Song B; Li X
Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
[TBL] [Abstract][Full Text] [Related]
2. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
[TBL] [Abstract][Full Text] [Related]
3. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
4. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
5. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
6. Association between Lipid-Lowering Drugs and Traumatic Subdural Hemorrhage: A Mendelian Randomization Study.
Chen K; Li H; Chen Y; Huang H; Wei L
J Integr Neurosci; 2024 Apr; 23(4):76. PubMed ID: 38682216
[TBL] [Abstract][Full Text] [Related]
7. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
8. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
9. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
[TBL] [Abstract][Full Text] [Related]
10. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
[TBL] [Abstract][Full Text] [Related]
11. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
12. Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.
Huang Q; Zhang Q; Cao B
Brain Behav; 2024 Jun; 14(6):e3543. PubMed ID: 38837845
[TBL] [Abstract][Full Text] [Related]
13. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
14. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
15. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
16. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
17. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
[TBL] [Abstract][Full Text] [Related]
18. Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization.
Wu T; Ye L; Wang S; Huang J; Zhang J
Front Pharmacol; 2023; 14():1258018. PubMed ID: 37964871
[No Abstract] [Full Text] [Related]
19. Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study.
Xu Y; Li Y
World Allergy Organ J; 2024 Apr; 17(4):100899. PubMed ID: 38623319
[TBL] [Abstract][Full Text] [Related]
20. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
